Donate Become a member Sign in
IFPA
Logo / Full logo
Global Actions

Advocacy

World Psoriasis Day

IFPA Accelerator

IFPA Forum

IFPA Conference

Projects

Resources & Tools
Join now

Become a member

Become a Partner

Start an Organization

Apply for Funding

Event Calendar

About Us

Global Team

Members

Our Cause

Search
Global Actions
Resources & Tools
Join now
About Us
search_purple
Donate Become a member Sign in

Deucravacitinib: An Oral treatment for adults living with moderate-to-severe plaque psoriasis approved by EMA- Bristol Myers Squibb

30 January 2023

By IFPA

Sign up to our newsletter

Join now
Donate
Privacy policy
Whistleblower Policy
Facebook
Instagram
LinkedIn
Twitter
Tik Tok
YouTube